Progress towards Clinical Use of iPS Cell Derived Therapies
(2016) In International Journal of Stem Cell Research & Therapy- Abstract
- A decade has passed since Shinya Yamanaka published his
landmarking publication on how to produce pluripotent stem-
cell-like cells and the term induced pluripotent stem cells, iPS
cells, was coined. This past decade has been a decade devoted
to pluripotent cells, scrutinizing molecular mechanisms in cell
identity, and optimizing derivation methods, culture conditions
and characterization methods to xenofree and chemically defined
clinical-grade pluripotent stem cells. The early promises of
autologous cell therapies are now replaced by creation of highly
selected donor cell banks matched to provide cells for the majority
of a target ... (More) - A decade has passed since Shinya Yamanaka published his
landmarking publication on how to produce pluripotent stem-
cell-like cells and the term induced pluripotent stem cells, iPS
cells, was coined. This past decade has been a decade devoted
to pluripotent cells, scrutinizing molecular mechanisms in cell
identity, and optimizing derivation methods, culture conditions
and characterization methods to xenofree and chemically defined
clinical-grade pluripotent stem cells. The early promises of
autologous cell therapies are now replaced by creation of highly
selected donor cell banks matched to provide cells for the majority
of a target population. Several of the initial safety concerns with
iPS cells have been addressed with the use of non-integrating
derivation methods and chemically defined and xenofree culture
conditions, but some remain and will not be fully resolved until
conclusions from in vivo experiments in larger animal models
can be made. Published studies on safety and proof of concept
performed in nonhuman primates are few but show promising
results for spinal cord injury and Parkinson’s disease for example.
But questions remain; on how to provide functional and long-term
integrating grafts and whether these can fulfill the promises of
recovery and potential cure? (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/f98e781e-fc88-4a02-abd9-0d9d27bac6bd
- author
- Kele, Malin and Falk, Anna LU
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Stem Cell Research & Therapy
- publisher
- ClinMed International Library
- ISSN
- 2469-570X
- language
- English
- LU publication?
- no
- id
- f98e781e-fc88-4a02-abd9-0d9d27bac6bd
- date added to LUP
- 2021-08-10 14:11:10
- date last changed
- 2021-08-12 14:31:53
@misc{f98e781e-fc88-4a02-abd9-0d9d27bac6bd, abstract = {{A decade has passed since Shinya Yamanaka published his <br/>landmarking publication on how to produce pluripotent stem-<br/>cell-like cells and the term induced pluripotent stem cells, iPS <br/>cells, was coined. This past decade has been a decade devoted <br/>to pluripotent cells, scrutinizing molecular mechanisms in cell <br/>identity, and optimizing derivation methods, culture conditions <br/>and characterization methods to xenofree and chemically defined <br/>clinical-grade pluripotent stem cells. The early promises of <br/>autologous cell therapies are now replaced by creation of highly <br/>selected donor cell banks matched to provide cells for the majority <br/>of a target population. Several of the initial safety concerns with <br/>iPS cells have been addressed with the use of non-integrating <br/>derivation methods and chemically defined and xenofree culture <br/>conditions, but some remain and will not be fully resolved until <br/>conclusions from in vivo experiments in larger animal models <br/>can be made. Published studies on safety and proof of concept <br/>performed in nonhuman primates are few but show promising <br/>results for spinal cord injury and Parkinson’s disease for example. <br/>But questions remain; on how to provide functional and long-term <br/>integrating grafts and whether these can fulfill the promises of <br/>recovery and potential cure?}}, author = {{Kele, Malin and Falk, Anna}}, issn = {{2469-570X}}, language = {{eng}}, note = {{Review}}, publisher = {{ClinMed International Library}}, series = {{International Journal of Stem Cell Research & Therapy}}, title = {{Progress towards Clinical Use of iPS Cell Derived Therapies}}, url = {{https://lup.lub.lu.se/search/files/101078546/Progress_towards_Clinical_Use_.pdf}}, year = {{2016}}, }